Zepbound & Mounjaro (Tirzepatide): The Dual-Action GLP-1 Explained

What is tirzepatide?

Tirzepatide is the generic (non-proprietary) name of a medication developed and manufactured by Eli Lilly and Company. It's a once-weekly subcutaneous injection — a small shot you give yourself under the skin of the abdomen, thigh, or upper arm, usually with a single-dose pen. Like the GLP-1 receptor agonists it's often grouped with, it lowers blood sugar and powerfully reduces appetite, but its underlying design is a step beyond a simple GLP-1 drug.

What makes tirzepatide distinctive is that it activates two gut-hormone receptors at once. It's a dual agonist of both the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide) — which is why it's sometimes called a "twincretin." Pure GLP-1 drugs such as semaglutide hit only one of those targets. We explain the underlying biology of these incretin hormones in our guide to what GLP-1 actually is.

Tirzepatide at a glance

Mounjaro vs. Zepbound: same drug, two names

This is the single most common point of confusion, so let's be clear: Mounjaro and Zepbound contain the identical molecule — tirzepatide — at the identical strengths. The difference is purely which condition each brand is FDA-approved to treat, a regulatory and marketing distinction rather than a chemical one.

• Mounjaro is approved for type 2 diabetes, where it lowers blood sugar (A1c) and is used alongside diet and exercise.
• Zepbound is approved for chronic weight management in adults with obesity, or who are overweight with a weight-related condition such as high blood pressure or high cholesterol.
• In late 2024, Zepbound gained an additional approval for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity — the first drug approved for that condition.

This mirrors how its main rival is split: semaglutide is "Ozempic" for diabetes and "Wegovy" for weight loss. The two-brand approach matters in practice mostly for insurance coverage, since plans cover diabetes and obesity drugs very differently — see our cost and insurance guide for why that distinction can change what you pay.

How tirzepatide works

Both GLP-1 and GIP are incretin hormones — gut hormones released after eating that amplify the body's insulin response. By switching on both receptors, tirzepatide produces several coordinated effects:

• It boosts insulin when blood sugar is high, in a glucose-dependent way, so it rarely causes dangerous lows on its own.
• It slows gastric emptying, so food leaves the stomach more gradually and you feel full longer.
• It acts on appetite centers in the brain, reducing hunger and "food noise."
• The added GIP activity is thought to further improve how the body handles fat and sugar, which may help explain tirzepatide's larger effects compared with GLP-1-only drugs.

As with other drugs in this family, the molecule is engineered to resist the enzyme that destroys natural incretins within minutes, so a single weekly dose keeps working for about a week.

Tirzepatide dosing schedule

Tirzepatide is always titrated — started low and stepped up slowly — to reduce the gastrointestinal side effects that are worst at the beginning. The 2.5 mg dose is a starter dose meant to ease your body in, not a therapeutic target. The full ladder runs:

Doses are generally increased no sooner than every 4 weeks, and not everyone reaches 15 mg — many people do well on a lower maintenance dose. Your clinician tailors the target to your response and how well you tolerate each step.

How much weight can you lose on tirzepatide?

The headline numbers come from SURMOUNT-1, the pivotal obesity trial published in the New England Journal of Medicine in 2022. In it, participants without diabetes who took the highest dose lost on average about 20–22% of their body weight over 72 weeks, alongside lifestyle changes — the largest average weight loss of any single approved agent to date.

For type 2 diabetes, the SURPASS trial program showed tirzepatide substantially lowers A1c, often more than the comparator diabetes drugs it was tested against. As always, these are averages: some people lose far more, some much less, and — as with all drugs in this class — weight tends to return after stopping, because the underlying biology of appetite resumes. Our weight-loss guide breaks down what to realistically expect.

Tirzepatide vs. semaglutide (Zepbound vs. Wegovy)

The most-asked comparison is between tirzepatide and semaglutide, the active ingredient in Wegovy and Ozempic. The core difference is mechanistic — dual vs. single receptor — and it shows up in the weight-loss numbers.

*Trial averages at the highest dose alongside lifestyle changes; individual results vary. A head-to-head trial (SURMOUNT-5) also favored tirzepatide.

The practical takeaway: tirzepatide tends to produce more average weight loss, likely thanks to that second (GIP) receptor, while both share a similar side-effect profile and weekly-injection format. Cost, insurance coverage, and individual tolerability often matter just as much as the headline percentage when choosing. See how every option stacks up in our GLP-1 medications comparison.

Side effects and safety

Because tirzepatide slows digestion, its most common side effects are gastrointestinal: nausea, diarrhea, vomiting, and constipation. These are usually worst when starting or stepping up a dose and tend to ease over time — which is the whole reason for the slow titration schedule above.

It also carries the same serious class warnings as other incretin drugs. There is a boxed warning about thyroid C-cell tumors based on rodent studies, and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or the genetic syndrome MEN 2. Clinicians also use caution given risks of pancreatitis and gallbladder problems. It's not used in pregnancy. We cover the full picture, including how to reduce nausea, in our dedicated GLP-1 side effects guide.

The bottom line

Tirzepatide is the most potent single weight-management medication approved to date, and its dual GIP/GLP-1 design is the reason. Sold as Mounjaro for diabetes and Zepbound for obesity and sleep apnea, it's the same once-weekly injection either way, titrated from 2.5 mg up to 15 mg. It includes GLP-1 activity but is technically a dual agonist, not a pure GLP-1 — a small distinction with a big payoff in the trials. Like all of these drugs, it's a prescription treatment that manages chronic conditions rather than curing them, and it belongs in a conversation with a clinician.

From here, compare it directly against Wegovy (semaglutide), or see the full lineup in our GLP-1 medications guide.

Frequently asked questions